申请人:Daiichi Sankyo Company, Limited
公开号:EP3650045A1
公开(公告)日:2020-05-13
An object of the present invention is to provide a medicine that can simply treat and/or prevent a retinal degenerative disease associated with photoreceptor degeneration, including retinitis pigmentosa. The solution is to provide an agent for treating and/or preventing a retinal degenerative disease associated with photoreceptor degeneration, containing a compound having a retinoic acid receptor agonistic activity (for example, tamibarotene, tamibarotene methyl ester, tamibarotene ethyl ester, tazarotene, tazarotenic acid, adapalene, palovarotene, retinol, isotretinoin, alitretinoin, etretinate, acitretin or bexarotene) or a salt thereof.
本发明的目的是提供一种能够简单治疗和/或预防与感光细胞变性相关的视网膜变性疾病(包括视网膜色素变性)的药物。本发明的解决方案是提供一种用于治疗和/或预防与感光细胞变性相关的视网膜变性疾病的药剂,该药剂含有一种具有视黄酸受体激动活性的化合物(例如、他米巴罗汀、他米巴罗汀甲酯、他米巴罗汀乙酯、他扎罗汀、他扎罗汀酸、阿达帕林、帕罗伐汀、视黄醇、异维甲酸、阿立维甲酸、依曲替酯、阿曲汀或贝沙罗汀)或其盐。